<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04030689</url>
  </required_header>
  <id_info>
    <org_study_id>19-PP-11</org_study_id>
    <nct_id>NCT04030689</nct_id>
  </id_info>
  <brief_title>Free HIV Testing in Private Biological Laboratories: A New Offer to Encourage HIV Testing</brief_title>
  <acronym>ALSO</acronym>
  <official_title>&quot;Au Labo Sans Ordo &quot;: A 12 Month Local Experimentation of Free HIV Testing Without Prescription in Private Medical and Biological Laboratories in Paris and in the Alpes-Maritimes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nice</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nice</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The program &quot; Au labo sans ordo &quot; aims to increase HIV testing coverage, in order to improve&#xD;
      the first stage of the HIV care cascade in Paris and the Alpes-Maritimes, areas facing a much&#xD;
      higher HIV epidemic than the other regions in metropolitan France. Both departments are&#xD;
      engaged in the Fast Track Cities Initiative.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The program relies on the hypothesis that the opportunity to get tested for HIV for free&#xD;
      (called VihTest) in any Private Laboratory (PL), without prior appointment nor prescription,&#xD;
      combined with an intense targeted promotion and communication strategy, will significantly&#xD;
      increase the testing coverage. This offer might remove some of the multiple barriers to HIV&#xD;
      testing and ease the move to action, in particular within key affected populations which&#xD;
      contribute to the largest part of the epidemic dynamic.&#xD;
&#xD;
      This program offers a new access to HIV testing. It is developed jointly by local&#xD;
      authorities, the health insurance and state regional health agencies, in response to the very&#xD;
      low increase of HIV testing coverage despite a diversification of the testing supply and&#xD;
      national recommendations for generalized and repeated HIV testing within key populations.&#xD;
&#xD;
      The experimentation will be implemented for 12 months in all Private Laboratories in Paris&#xD;
      (164) and the Alpes-Maritimes (107), targeting a 15% increase in the total volume of tests&#xD;
      performed outside of hospital settings.&#xD;
&#xD;
      The evaluation process will focus on:&#xD;
&#xD;
      Axis 1 : The number of tests performed and the number of new HIV diagnosis considering the&#xD;
      potential substitution effect towards the current testing provision through CeGIDD (free&#xD;
      Centers for Information, Diagnosis and Testing) and community-based outreach testing&#xD;
      programs.&#xD;
&#xD;
      Axis 2 : The linkage to care following an HIV positive test will be organized and documented&#xD;
      and the characteristic of HIV+ population diagnosed after VihTest will be describe&#xD;
      (ALSO_PARCOURS) Axis 3: The characteristics of the program's users will be collected and&#xD;
      compared 1) to those of PL attendants with a medical prescription for an HIV test and 2) to&#xD;
      CeGIDD clients.&#xD;
&#xD;
      Axis 4: The feasibility and acceptability of the program by the PL's staff will be documented&#xD;
      using detailed qualitative questionnaire; Axis 5: The cost-effectiveness of scaling-up such a&#xD;
      testing strategy and its budgetary impact will be assessed through a microcoasting&#xD;
      evalutation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">July 1, 2019</start_date>
  <completion_date type="Anticipated">March 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Positive VihTest</measure>
    <time_frame>548 days</time_frame>
    <description>Number of patients enrolled in the study with demographics, risk factors, clinical therapeutic and biological characteristics</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>HIV Seropositivity</condition>
  <condition>HIV Testing</condition>
  <arm_group>
    <arm_group_label>Axis 2</arm_group_label>
    <description>Each patient diagnosed HIV positive following VihTest test will be invited to participate to ALSO-Parcours; This program aimed to decribe the link to care for this population and to make a descriptive analysis of this HIV+ patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>data collected from patient file</intervention_name>
    <description>socio-demographics, previous HIV testing history, history of HIV contamination, clinics HIV related data will be collected for each patient who notified his non-objection to participate to this non interventional study.</description>
    <arm_group_label>Axis 2</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Axis 2 Major patient diagnosed HIV positive after a VihTest in a Private Laboratory in&#xD;
        Paris or in the Alpes Maritimes.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Axis 2&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Major&#xD;
&#xD;
          -  being diagnosed HIV positive after a VihTest&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Minor&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pascal PUGLIESE, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire de Nice</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vanina OLIVERI</last_name>
    <phone>492034254</phone>
    <phone_ext>+33</phone_ext>
    <email>oliveri.v@chu-nice.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hopital l'Archet Service Infectiologie</name>
      <address>
        <city>Nice</city>
        <zip>06200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irit TOUITOU, PhD</last_name>
      <phone>492035847</phone>
      <phone_ext>+33</phone_ext>
      <email>touitou.i@chu-nice.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 19, 2019</study_first_submitted>
  <study_first_submitted_qc>July 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2019</study_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV Testing</keyword>
  <keyword>Combined HIV prevention</keyword>
  <keyword>Linkage to care</keyword>
  <keyword>Implementation plan</keyword>
  <keyword>Cost-effectiveness</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Seropositivity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

